Shantel
Key Takeaways:
- James Kaufman has been appointed as Chief Commercial Officer (CCO) at Serac Imaging Systems, leading the commercialisation of Seracam®.
- With nearly 30 years in the global healthcare and molecular imaging industry, Kaufman brings a wealth of experience and deep industry knowledge to his new role.
- His responsibilities will include physician marketing and sales, business development, operations, supply chain, and brand team management.
- Seracam® is a portable hybrid gamma-optical camera for medical imaging that is set to revolutionize patient care in diverse settings.
About James Kaufman
James Kaufman, commonly known as Jim, has amassed nearly 30 years of experience in the global healthcare and molecular imaging industry. Before joining Serac Imaging Systems, he served as Vice President of Global Sales at Jubilant Radiopharma. His key areas of expertise span direct to physician marketing and sales, business development, operations, supply chain, and brand team management. He holds specialised knowledge in nuclear medicine and molecular imaging across cardiology, neurology, oncology, and general nuclear imaging segments.
Kaufman’s educational background includes a Bachelor of Science in Business Administration and Marketing from Ashland University, Ashland, Ohio. He received his Nuclear Medicine Technology training at The Ohio State University and is Board Certified in Nuclear Medicine Technology.
About Seracam®
Seracam® is a highly portable, compact hybrid optical-gamma camera in development by Serac Imaging Systems. The goal is to bring high-resolution molecular imaging to a patient’s bedside in a variety of settings, such as operating rooms, intensive care units, or physician’s offices. The combination of a gamma image overlaid with a co-aligned optical image of the same region of interest can help improve understanding of a patient’s condition and their optimal treatment path. Currently, Seracam® is for investigational use only and is not offered for sale. It has not been cleared or approved by the FDA or UK and European regulatory authorities.
Leadership Commentary
“We are excited to welcome Jim to the team at such a pivotal point, with clinical testing of Seracam now well underway, and feedback from patients and physicians imminent,” stated Mark Rosser, Chief Executive Officer of Serac Imaging Systems. “With his wealth of experience in nuclear medicine and medical imaging, combined with his business development prowess, Jim will play a significant role in driving Seracam forward through its next stages of development.”
Kaufman echoed Rosser’s enthusiasm, stating, “Serac Imaging Systems’ approach, designing a product for unmet diagnostic needs from the ground up using cutting-edge technology, has the potential to be a game changer for patient care. I am excited to work with Mark and his team to bring Seracam’s breakthrough molecular imaging technology to new patient populations in diverse locations, thereby extending imaging options, increasing productivity and ultimately patient outcomes.”
For more information on Serac Imaging Systems and Seracam®, visit www.seracimagingsystems.com.
About Serac Imaging Systems
Serac Imaging Systems is a medical technology company specializing in the development of innovative, portable imaging solutions. It is a wholly-owned subsidiary of Serac Life Sciences Limited.
